Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
about
The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.Towards a molecular understanding of polycythemia rubra vera.Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesisRegulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERKDecreased level of PDCD4 (programmed cell death 4) protein activated cell proliferation in the lung of A/J mouse.The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization.Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase.Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.Modulation of urokinase plasminogen activator system by poly(ADP-ribose)polymerase-1 inhibition.Matrilysin (matrix metalloprotease-7) cleaves membrane-bound annexin II and enhances binding of tissue-type plasminogen activator to cancer cell surfaces.Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.Induction of p53 by urokinase in lung epithelial cells.Urokinase induces its own expression in Beas2B lung epithelial cells.ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line.Gene response of human skin fibroblasts to urokinase- and tissue-type plasminogen activators.Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.Evidence for intracellular cleavage of plasminogen activator inhibitor type 2 (PAI-2) in normal epidermal keratinocytes.Ribotoxic stress response to the trichothecene deoxynivalenol in the macrophage involves the SRC family kinase Hck.
P2860
Q30303631-B769CA7B-D74A-4C77-B2A5-BF80DE589A1FQ30304130-74F51B96-01DF-4449-AFD8-E04E22D5823AQ30307084-BA7907F2-7F77-48A8-B9FD-57EEAD18F7ECQ31506532-ACA945DE-6596-421C-8C90-34B8F7B30F16Q33687878-9EA52832-16C1-42FC-B25C-676389CD78B2Q33695003-C0F3B61D-F478-46A0-8A01-8C1B34DB9EC8Q33940318-D263A8C7-6607-4785-B6FF-F009DC3D39D2Q34119101-5E2C2277-94A9-4C45-91CB-4F12EBB539ADQ34410643-E4B9C127-468F-428C-8BD6-D8DA4B731338Q34525272-8EF70D73-2610-48AA-A46D-6D827463129BQ34606581-1DA96649-2D38-42C1-954E-F4D89394A90BQ35213763-E1BDC903-4A0E-4ED1-9FD8-C753D8CF7197Q36433505-22341A85-F624-47ED-9080-4246278A9D21Q36805290-711A82EE-C33B-4B1B-AD15-161AE7B00B24Q36882273-97C75E9C-DFE0-45A2-B83E-7F93E322EBBBQ37093692-FE7E43BF-35C9-48CE-8BD8-78E5CD568816Q37603401-865C9CEE-4F38-4461-8E8A-92FB879248EEQ38932536-E6D3AF9F-2025-489C-ABCA-C8F1FD071371Q39948157-E9A3765E-CDAE-4A1A-A531-27E27EDD9880Q40141648-8A651090-4E3C-40FD-9601-5CE2516A8F49Q40293146-1E9B9291-4562-495C-B979-92D6D59CEC85Q40413239-692F82A3-5EFA-41C8-AD72-32B801722B06Q40718884-2A41B50E-303B-4795-BE32-6040E7B8F6DFQ40786621-A4B441C4-8218-4949-A33D-273308A5295DQ40881455-4544BD17-98D0-4873-BEAF-AA59F42DE9C3Q41667528-9D746DAE-26F7-40AE-A74D-9201A924A231Q41910807-4DC06FE9-E0E7-49D0-84C8-827A08F9685AQ41934121-B20CBA96-B7BC-4A38-A629-2BE5AA480F0CQ42478267-A1767170-4DF4-48E3-9AE4-7AEFA1BAD5C2Q42481882-ED5E4B9F-B601-4D40-9DA9-EACC707CE8ABQ46384510-1ABFF1D3-CB79-4409-891F-D4A9BC23F4EC
P2860
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
@en
type
label
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
@en
prefLabel
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
@en
P2093
P1433
P1476
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction.
@en
P2093
M Konakova
W D Schleuning
P304
P356
10.1046/J.1432-1327.1998.2530421.X
P407
P577
1998-04-01T00:00:00Z